Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rapid therapy changes fall short for metastatic GIST

Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Publish date:: August 17, 2018

Key clinical point: The strategy of rapid alteration of drugs to overcome mutations conferring imatinib resistance in gastrointestinal stromal tumor (GIST) was feasible but ineffective.

Major finding: There were no objective responses among 12 patients treated with the strategy.

Study details: A phase Ib clinical trial in 12 patients with heavily pretreated metastatic GIST.

Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano-Garcia disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.

Source: Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Read the article.

Citation:

Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in GIST

Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.

Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.

Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.

In GIST, KIT inhibitor may be of benefit in all post-imatinib lines of therapy, George S et al. ASCO 2018. Abstract 11511.

Sunitinib with regorafenib falls short for metastatic GIST, Serrano C et al. ASCO 2018 Abstract 11510.